Trial Profile
A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus (EASE-2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EASE-2
- Sponsors Boehringer Ingelheim
- 16 Jul 2019 According to European Union Clinical Trials Registry Japan was in planned location.
- 11 Jun 2019 Modeling and simulation data from studies EASE-1,2 and 3 were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 04 Oct 2018 Results presented in a Boehringer Ingelheim media release.